Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jul;65(1):34–41. doi: 10.1136/jnnp.65.1.34

Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy

T Baldeweg 1, J Catalan 1, B Gazzard 1
PMCID: PMC2170165  PMID: 9667558

Abstract

OBJECTIVE—To determine the incidence of HIV dementia and opportunistic brain disease in AIDS relative to the use of licensed antiretoviral medication (zidovudine, zalcitabine, didanosine, and stavudine).
METHOD—Medical records were evaluated retrospectively in a longitudinal cohort of 1109 patients with AIDS during the period 1991-4. Treatment groups were defined by start and duration of zidovudine treatment, the drugs used most often during this period were: (a) no zidovudine, (b) zidovudine before AIDS, (c) zidovudine before and after AIDS, and (d) zidovudine used in AIDS. Main outcome measures were cumulative incidence and survival from AIDS to onset of HIV dementia, progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis, and primary CNS lymphoma.
RESULTS—Risk of brain disease including HIV dementia and opportunistic brain disease was reduced in patients who started zidovudine before AIDS and continued in AIDS (relative risk (RR) 0.55, 95% confidence interval (95% CI) 0.36-0.84) as well as zidovudine initiated in AIDS (RR 0.27, 95% CI 0.17-0.45) compared with untreated subjects. Treatment effects were not constant over time, decreasing by 14%-32% for each six months of follow up. This was supported by unadjusted incidences across groups stratified by duration of zidovudine use, indicating reduced risk with treatment for up to 18 months but not with longer duration of use of zidovudine. Other antiretroviral drugs had no significant effect, although these were used by only 14% of patients in this cohort.
CONCLUSION—The time limited but effective neuroprotection offered by zidovudine monotherapy for <18 months suggests that non-specific mechanisms of cerebral immunological defence may benefit from antiretroviral treatment. Due to the limitations of a retrospective study these findings require confirmation and further investigation in the context of current combination drug treatments.



Full Text

The Full Text of this article is available as a PDF (138.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Achim C. L., Morey M. K., Wiley C. A. Expression of major histocompatibility complex and HIV antigens within the brains of AIDS patients. AIDS. 1991 May;5(5):535–541. doi: 10.1097/00002030-199105000-00009. [DOI] [PubMed] [Google Scholar]
  2. Bacellar H., Muñoz A., Miller E. N., Cohen B. A., Besley D., Selnes O. A., Becker J. T., McArthur J. C. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology. 1994 Oct;44(10):1892–1900. doi: 10.1212/wnl.44.10.1892. [DOI] [PubMed] [Google Scholar]
  3. Bagasra O., Lavi E., Bobroski L., Khalili K., Pestaner J. P., Tawadros R., Pomerantz R. J. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS. 1996 Jun;10(6):573–585. doi: 10.1097/00002030-199606000-00002. [DOI] [PubMed] [Google Scholar]
  4. Baldeweg T., Catalan J., Lovett E., Gruzelier J., Riccio M., Hawkins D. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection. AIDS. 1995 Jun;9(6):589–596. doi: 10.1097/00002030-199506000-00010. [DOI] [PubMed] [Google Scholar]
  5. Baldeweg T., Riccio M., Gruzelier J., Hawkins D., Burgess A., Irving G., Stygall J., Catt S., Catalan J. Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: a longitudinal placebo-controlled study. J Neurol Sci. 1995 Oct;132(2):162–169. doi: 10.1016/0022-510x(95)00140-w. [DOI] [PubMed] [Google Scholar]
  6. Baumgartner J. E., Rachlin J. R., Beckstead J. H., Meeker T. C., Levy R. M., Wara W. M., Rosenblum M. L. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990 Aug;73(2):206–211. doi: 10.3171/jns.1990.73.2.0206. [DOI] [PubMed] [Google Scholar]
  7. Brew B. J., Bhalla R. B., Paul M., Sidtis J. J., Keilp J. J., Sadler A. E., Gallardo H., McArthur J. C., Schwartz M. K., Price R. W. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS. 1992 May;6(5):461–465. [PubMed] [Google Scholar]
  8. Brew B. J., Dunbar N., Druett J. A., Freund J., Ward P. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. AIDS. 1996 Oct;10(12):1357–1360. doi: 10.1097/00002030-199610000-00007. [DOI] [PubMed] [Google Scholar]
  9. Carr A., Tindall B., Brew B. J., Marriott D. J., Harkness J. L., Penny R., Cooper D. A. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992 Jul 15;117(2):106–111. doi: 10.7326/0003-4819-117-2-106. [DOI] [PubMed] [Google Scholar]
  10. Chiesi A., Vella S., Dally L. G., Pedersen C., Danner S., Johnson A. M., Schwander S., Goebel F. D., Glauser M., Antunes F. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):39–44. doi: 10.1097/00042560-199601010-00005. [DOI] [PubMed] [Google Scholar]
  11. Conway B., Halliday W. C., Brunham R. C. Human immunodeficiency virus-associated progressive multifocal leukoencephalopathy: apparent response to 3'-azido-3'-deoxythymidine. Rev Infect Dis. 1990 May-Jun;12(3):479–482. doi: 10.1093/clinids/12.3.479. [DOI] [PubMed] [Google Scholar]
  12. Fiala M., Cone L. A., Cohen N., Patel D., Williams K., Casareale D., Shapshak P., Tourtelotte W. Responses of neurologic complications of AIDS to 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine. I. Clinical features. Rev Infect Dis. 1988 Mar-Apr;10(2):250–256. doi: 10.1093/clinids/10.2.250. [DOI] [PubMed] [Google Scholar]
  13. Garrote F. J., Molina J. A., Lacambra C., Mollejo M., Madero S., del Ser T. Ineficacia de la zidovudina (AZT) en la leucoencefalopatía multifocal progresiva (LMP) asociada al síndrome de inmunodeficiencia adquirida (SIDA). Rev Clin Esp. 1990 Nov;187(8):404–407. [PubMed] [Google Scholar]
  14. Girard P. M., Landman R., Gaudebout C., Olivares R., Saimot A. G., Jelazko P., Gaudebout C., Certain A., Boué F., Bouvet E. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993 May 27;328(21):1514–1520. doi: 10.1056/NEJM199305273282102. [DOI] [PubMed] [Google Scholar]
  15. Glass J. D., Fedor H., Wesselingh S. L., McArthur J. C. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995 Nov;38(5):755–762. doi: 10.1002/ana.410380510. [DOI] [PubMed] [Google Scholar]
  16. Glass J. D., Wesselingh S. L., Selnes O. A., McArthur J. C. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology. 1993 Nov;43(11):2230–2237. doi: 10.1212/wnl.43.11.2230. [DOI] [PubMed] [Google Scholar]
  17. Gray F., Bélec L., Keohane C., De Truchis P., Clair B., Durigon M., Sobel A., Gherardi R. Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS. 1994 Apr;8(4):489–493. doi: 10.1097/00002030-199404000-00011. [DOI] [PubMed] [Google Scholar]
  18. Hansen N. J., Madsen C., Stenager E. Progressiv multifokal leukoencefalopati. Ugeskr Laeger. 1995 Jan 16;157(3):284–288. [PubMed] [Google Scholar]
  19. Ioannidis J. P., Cappelleri J. C., Lau J., Skolnik P. R., Melville B., Chalmers T. C., Sacks H. S. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med. 1995 Jun 1;122(11):856–866. doi: 10.7326/0003-4819-122-11-199506010-00009. [DOI] [PubMed] [Google Scholar]
  20. Leport C., Chakroun M., Matheron S., Rozenbaum W., Dournon E., Regnier B. Efficacité et tolérance de la zidovudine chez 32 malades atteints de toxoplasmose cérébrale au cours du syndrome dímmunodéficit acquis. Presse Med. 1988 Oct 15;17(35):1813–1814. [PubMed] [Google Scholar]
  21. Lin J. C., Zhang Z. X., Chou T. C., Sim I., Pagano J. S. Synergistic inhibition of Epstein-Barr virus: transformation of B lymphocytes by alpha and gamma interferon and by 3'-azido-3'-deoxythymidine. J Infect Dis. 1989 Feb;159(2):248–254. doi: 10.1093/infdis/159.2.248. [DOI] [PubMed] [Google Scholar]
  22. Lin J. C., Zhang Z. X., Smith M. C., Biron K., Pagano J. S. Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus. Antimicrob Agents Chemother. 1988 Feb;32(2):265–267. doi: 10.1128/aac.32.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lortholary O., Pialoux G., Dupont B., Trotot P., Vazeux R., Mikol J., Thiebaut J. B., Gonzalez-Canali G. Prolonged survival of a patient with AIDS and progressive multifocal leukoencephalopathy. Clin Infect Dis. 1994 May;18(5):826–827. doi: 10.1093/clinids/18.5.826. [DOI] [PubMed] [Google Scholar]
  24. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  25. Maehlen J., Dunlop O., Liestøl K., Dobloug J. H., Goplen A. K., Torvik A. Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment. AIDS. 1995 Oct;9(10):1165–1169. [PubMed] [Google Scholar]
  26. Mar E. C., Chu C. K., Lin J. C. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res. 1995 Sep;28(1):1–11. doi: 10.1016/0166-3542(95)92835-b. [DOI] [PubMed] [Google Scholar]
  27. Martín-Suárez I., Aguayo Canela M., Merińo Muñoz D., Pujol de la Llave E. Supervivencia prolongada en enfermos con leucoencefalopatía multifocal progresiva asociada a SIDA tratados con altas dosis de zidovudina. Rev Clin Esp. 1994 Feb;194(2):136–138. [PubMed] [Google Scholar]
  28. McArthur J. C., Hoover D. R., Bacellar H., Miller E. N., Cohen B. A., Becker J. T., Graham N. M., McArthur J. H., Selnes O. A., Jacobson L. P. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993 Nov;43(11):2245–2252. doi: 10.1212/wnl.43.11.2245. [DOI] [PubMed] [Google Scholar]
  29. Moses A. V., Stenglein S. G., Nelson J. A. HIV infection of the brain microvasculature and its contribution to the AIDS dementia complex. J NeuroAIDS. 1996;1(1):85–99. doi: 10.1300/j128v01n01_04. [DOI] [PubMed] [Google Scholar]
  30. Padgett B. L., Walker D. L., ZuRhein G. M., Eckroade R. J., Dessel B. H. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971 Jun 19;1(7712):1257–1260. doi: 10.1016/s0140-6736(71)91777-6. [DOI] [PubMed] [Google Scholar]
  31. Portegies P. AIDS dementia complex: a review. J Acquir Immune Defic Syndr. 1994;7 (Suppl 2):S38–S49. [PubMed] [Google Scholar]
  32. Portegies P., Brew B. J. Update on HIV-related neurological illness. AIDS. 1991;5 (Suppl 2):S211–S217. doi: 10.1097/00002030-199101001-00029. [DOI] [PubMed] [Google Scholar]
  33. Portegies P., Enting R. H., de Gans J., Algra P. R., Derix M. M., Lange J. M., Goudsmit J. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS. 1993 May;7(5):669–675. [PubMed] [Google Scholar]
  34. Portegies P., Enting R. H., de Jong M. D., Danner S. A., Reiss P., Goudsmit J., Lange J. M. AIDS dementia complex and didanosine. Lancet. 1994 Sep 10;344(8924):759–759. doi: 10.1016/s0140-6736(94)92252-7. [DOI] [PubMed] [Google Scholar]
  35. Portegies P. HIV-1, the brain, and combination therapy. Lancet. 1995 Nov 11;346(8985):1244–1245. doi: 10.1016/s0140-6736(95)91857-4. [DOI] [PubMed] [Google Scholar]
  36. Portegies P. Review of antiretroviral therapy in the prevention of HIV-related AIDS dementia complex (ADC). Drugs. 1995;49 (Suppl 1):25–40. doi: 10.2165/00003495-199500491-00007. [DOI] [PubMed] [Google Scholar]
  37. Portegies P., de Gans J., Lange J. M., Derix M. M., Speelman H., Bakker M., Danner S. A., Goudsmit J. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ. 1989 Sep 30;299(6703):819–821. doi: 10.1136/bmj.299.6703.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Price R. W. Neurological complications of HIV infection. Lancet. 1996 Aug 17;348(9025):445–452. doi: 10.1016/S0140-6736(95)11035-6. [DOI] [PubMed] [Google Scholar]
  39. Renold C., Sugar A., Chave J. P., Perrin L., Delavelle J., Pizzolato G., Burkhard P., Gabriel V., Hirschel B. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) 1992 Jul;71(4):224–239. doi: 10.1097/00005792-199207000-00005. [DOI] [PubMed] [Google Scholar]
  40. Rosenberg N. L., Hochberg F. H., Miller G., Kleinschmidt-DeMasters B. K. Primary central nervous system lymphoma related to Epstein-Barr virus in a patient with acquired immune deficiency syndrome. Ann Neurol. 1986 Jul;20(1):98–102. doi: 10.1002/ana.410200118. [DOI] [PubMed] [Google Scholar]
  41. Rottenberg D. A., Moeller J. R., Strother S. C., Sidtis J. J., Navia B. A., Dhawan V., Ginos J. Z., Price R. W. The metabolic pathology of the AIDS dementia complex. Ann Neurol. 1987 Dec;22(6):700–706. doi: 10.1002/ana.410220605. [DOI] [PubMed] [Google Scholar]
  42. Schmitt F. A., Bigley J. W., McKinnis R., Logue P. E., Evans R. W., Drucker J. L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988 Dec 15;319(24):1573–1578. doi: 10.1056/NEJM198812153192404. [DOI] [PubMed] [Google Scholar]
  43. Sidtis J. J., Gatsonis C., Price R. W., Singer E. J., Collier A. C., Richman D. D., Hirsch M. S., Schaerf F. W., Fischl M. A., Kieburtz K. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol. 1993 Apr;33(4):343–349. doi: 10.1002/ana.410330403. [DOI] [PubMed] [Google Scholar]
  44. Simpson D. M., Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med. 1994 Nov 15;121(10):769–785. doi: 10.7326/0003-4819-121-10-199411150-00008. [DOI] [PubMed] [Google Scholar]
  45. Singer E. J., Stoner G. L., Singer P., Tomiyasu U., Licht E., Fahy-Chandon B., Tourtellotte W. W. AIDS presenting as progressive multifocal leukoencephalopathy with clinical response to zidovudine. Acta Neurol Scand. 1994 Dec;90(6):443–447. doi: 10.1111/j.1600-0404.1994.tb02755.x. [DOI] [PubMed] [Google Scholar]
  46. Straus S. E., Cohen J. I., Tosato G., Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med. 1993 Jan 1;118(1):45–58. doi: 10.7326/0003-4819-118-1-199301010-00009. [DOI] [PubMed] [Google Scholar]
  47. Torres R. A., Barr M., Thorn M., Gregory G., Kiely S., Chanin E., Carlo C., Martin M., Thornton J. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med. 1993 Dec;95(6):573–583. doi: 10.1016/0002-9343(93)90352-p. [DOI] [PubMed] [Google Scholar]
  48. Tozzi V., Narciso P., Galgani S., Sette P., Balestra P., Gerace C., Pau F. M., Pigorini F., Volpini V., Camporiondo M. P. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS. 1993 May;7(5):683–692. doi: 10.1097/00002030-199305000-00012. [DOI] [PubMed] [Google Scholar]
  49. Tremblay M., Wainberg M. A. Susceptibility to AZT of HIV-1 variants grown in Epstein-Barr virus-transformed B cell lines. J Infect Dis. 1989 Jul;160(1):31–36. doi: 10.1093/infdis/160.1.31. [DOI] [PubMed] [Google Scholar]
  50. Vago L., Castagna A., Lazzarin A., Cinque P., Trabattoni G., Costanzi G. Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. Lancet. 1991 Jun 15;337(8755):1488–1488. doi: 10.1016/0140-6736(91)93186-d. [DOI] [PubMed] [Google Scholar]
  51. Vago L., Castagna A., Lazzarin A., Trabattoni G., Cinque P., Costanzi G. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr. 1993 Jan;6(1):42–45. [PubMed] [Google Scholar]
  52. Vion-Dury J., Nicoli F., Salvan A. M., Confort-Gouny S., Dhiver C., Cozzone P. J. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet. 1995 Jan 7;345(8941):60–61. doi: 10.1016/s0140-6736(95)91184-7. [DOI] [PubMed] [Google Scholar]
  53. Volberding P. A., Lagakos S. W., Grimes J. M., Stein D. S., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S., Phair J. P., Mitsuyasu R. T. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994 Aug 10;272(6):437–442. [PubMed] [Google Scholar]
  54. Wildemann B., Haas J., Ehrhart K., Wagner H., Lynen N., Storch-Hagenlocher B. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients. Neurology. 1993 Dec;43(12):2659–2663. doi: 10.1212/wnl.43.12.2659. [DOI] [PubMed] [Google Scholar]
  55. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES